Journal of Clinical Oncology
Articles in this Issue
Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).
6569 Background: IME, a first-in-class, direct, and competitive inhibitor of telomerase activity, was approved in the US for the tx of red blood cell (RBC...
Comparative analysis on genomic features of prostate cancer patients with and without treatment-emergent neuroendocrine prostate cancer: Perspective from liquid biopsy and tissue-based next generation sequencing.
e17067 Background: Treatment-emergent neuroendocrine prostate cancer (t-NEPC) serves as a highly aggressive variant of prostate cancer. Genomic features o...
Effect of in vivoengineered CAR-macrophages on physical barriers, tumor regression and immune memory to prevent tumor recurrence.
e14517 Background: The Chimera antigen receptor (CAR)-macrophages have emerged to treat solid tumors due to their high inf...
Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients.
9584 Background: ctDNA has emerged as a biomarker for minimal residual disease (MRD) detection in colorectal cancer and other cancer types. Its role in MR...
Artificial intelligence-powered real-time model for predicting recurrence and survival in head and neck squamous cell carcinoma after curative intent surgery.
6083 Background: Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 5.3% of cancer-related mortality worldwide, with an estimated 66...
Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study.
e16141 Background: This study investigated the efficacy and safety of camrelizumab in combination with paclitaxel and nedaplatin as preoperative therapy f...
Patient-reported acute and chronic toxicities from adjuvant therapies post resection of melanoma.
e21568 Background: One year ofadjuvant anti-programmed cell death protein-1 (anti-PD1) or dabrafenib-trametinib are standards of care for patients (pts) w...
Factors associated with outcomes following reduced intensity conditioning haploidentical hematopoietic cell transplantation in acute myeloid leukemia.
6560 Background: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for high-risk acute myeloid leukemia (AML). Elderly patients ca...
A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC.
8543 Background: SSGJ-707 is a recombinant humanized bispecific molecule built on IgG4 that targets the human programmed d...
Efficacy of venadaparib plus irinotecan in homologous recombination deficiency (HRD) gene mutations as 3+ line treatment in patients with metastatic gastric cancer (mGC).
4045 Background: Tumors with homologous recombination deficiency (HRD) have been suggested to be associated with a favorable response to poly (adenosine d...
Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosis.
6573 Background: There is currently no consensus on the optimal treatment for primary myelofibrosis (PMF) in pre-/early fibrotic stage (pre-PMF) and DIPPS...
Identifying profiles and mapping the patient journey in Japan with a large-scale digital survey of patients with prostate cancer (PC): Comparison with Western countries.
e17000 Background: A digital survey was conducted in Japan to capture patient and caregiver experiences of the PC journey, similar to a survey reported fr...
Comparison of outcomes for patients diagnosed with small cell lung cancer between a university and safety net hospital.
12077 Background: With immunotherapy, the five year overall survival (OS) for small cell lung cancer (SCLC) is 12%. However, real world factors such as so...
Comparative safety profiles of lutetium-177 and enzalutamide: A pharmacovigilance study and disproportionality analysis using real world data.
e15136 Background: Lutetium-177 represents a significant advancement in treating metastatic castration-resistant prostate cancer (mCRPC), showing a favora...
Biliary tract cancers: A large burden for little Rhode Island.
e22587 Background: Biliary tract cancers (BTCs) are a rare and aggressive group of malignancies characterized by rapid onset of treatment resistance and p...
SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with <i>HER2</i> -activating mutations.
TPS8648 Background: Approximately 2-4% of non-small cell lung cancer (NSCLC) harbor activating human epidermal growth fact...
Characterization of breast tumors and the tumor immune landscape in young, diverse participants of the Northern California Breast Cancer Family Registry.
e12551 Background: Racial and ethnic disparities in breast cancer mortality persist across breast cancer subtypes, and variations in immune response may c...
Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.
4574 Background: Enfortumab vedotin and pembrolizumab (EV/P) recently became the standard of care frontline treatment for patients with locally advanced o...
Association of KIT mutations with risk of central nervous system (CNS) metastasis (met) in patients (pts) with mucosal melanoma (MM).
9521 Background: The CNS is a frequent site of distant met in pts with cutaneous melanoma (CM). Previous studies have identified clinical, pathological, a...
Outcomes of post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance therapy in FLT3-mutated, IDH-mutated, or high relapse-risk myeloid malignancies: A single-center experience.
e18559 Background: Allogeneic hematopoietic stem cell transplant (HSCT) is potentially curative in acute myeloid leukemia (AML) and high-risk myelodysplas...
Promoting Resilience in Stress Management (PRISM): A randomized controlled trial of a psychosocial intervention for adolescents and young adults with advanced cancer.
10009 Background: Adolescents and Young Adults (AYAs) with advanced cancer report poor quality of life (QOL), high psychological distress, and minimal eng...
Circulating tumor DNA dynamics and pathologic response to neoadjuvant immunotherapy in resectable stage III melanoma.
e21560 Background: Pathologic response to neoadjuvant immunotherapy (NAI) can help predict recurrence in resectable stage III cutaneous melanoma. We inves...
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study.
e16407 Background: Recently, there has been an increase in the incidence of early-onset PDAC (EO-PDAC), which is conventionally defined as cancer occurrin...
Linking gene expression to tumor microenvironment using H&E features in stomach adenocarcinoma.
e14635 Background: Recent advances in computational pathology have revolutionized the analysis of histopathology images, enabling precise and rapid clinic...
Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation.
6568 Background: MDS risk assessed by the IPSS-R and IPSS-M at diagnosis impacts outcomes post-hematopoietic stem cell transplant (HSCT). Recent EBMT data...